1-哌嗪-1-基丙-2-醇 | 1074-54-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-哌嗪-1-基丙-2-醇
• 中文别名: α-甲基-1-哌嗪乙醇
• 英文名称: 1-(1-piperazinyl)-2-propanol
• 英文别名: 1-(2-hydroxypropyl)piperazine；1-methyl-2-(1-piperazinyl)ethanol；1-(Piperazin-1-yl)propan-2-ol；1-piperazin-1-ylpropan-2-ol
• CAS: 1074-54-0
• 化学式: C₇H₁₆N₂O
• mdl: MFCD00130195
• 分子量: 144.217
• InChiKey: XAKIZRLIXGLPBW-UHFFFAOYSA-N

物化性质

• 沸点：
  108.5 °C(Press: 10 Torr)
• 密度：
  1.0103 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  35.5
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933599090
• 危险标志：
  GHS06
• 危险性描述：
  H301
• 危险性防范说明：
  P301 + P310
• 包装等级：
  III
• 危险类别：
  8
• 危险品运输编号：
  2735
• 储存条件：
  储存条件：室温、避光、惰性气体环境中保存。

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 1-(1-Piperazinyl)-2-Propanol
: CBR01664
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 3), H301
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
T Toxic R25
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Danger
Hazard statement(s)
Toxic if swallowed.
Precautionary statement(s)
P301 + P310 IF SWALLOWED: Immediately call a POISON CENTER or doctor/
physician.
Supplemental Hazard none
Statements
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

---

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 144,22 g/mol
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
1-(1-Piperazinyl)-2-Propanol
Acute Tox. 3; H301 <= 100 %
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
1-(1-Piperazinyl)-2-Propanol
T, R25 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Take victim immediately to hospital. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Nature of decomposition products not known.
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Wear respiratory protection. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non-combustible, acute toxic Cat.3 / toxic hazardous materials or hazardous
materials causing chronic effects
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling
the product.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face particle
respirator type N99 (US) or type P2 (EN 143) respirator cartridges as a backup to engineering
controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use
respirators and components tested and approved under appropriate government standards such
as NIOSH (US) or CEN (EU).
Control of environmental exposure
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

---

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Dissolve or mix the material with a combustible solvent and burn in a chemical incinerator equipped with
an afterburner and scrubber. Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-哌嗪-1-基丙-2-醇 在 4-二甲氨基吡啶 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 、 苯 为溶剂， 反应 24.0h， 生成 2-<4-(2-tert-butoxycarbonylethyl)-1-piperazinyl>-1-methylethyl 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-3-indolylacetate
  参考文献：
  名称：

  Piperazinealkanol Ester Derivatives of Indomethacin as Dual Inhibitors of 5-Lipoxygenase and Cyclooxygenase.

  摘要：

  已经制备并测试了吲哚美辛的哌嗪烷醇酯衍生物对5-脂肪氧化酶（5-LO）和环氧合酶（CO）的抑制活性。它们抑制了豚鼠多形核白细胞的细胞质中5-羟基二十碳四烯酸（5-HETE）的形成以及洗涤兔血小板悬浮液中血栓烷B2（TXB2）的形成。在测试化合物中，2-[4-(2-羟乙基)-1-哌嗪基]-1-苯乙基 1-(4-氯苯甲酰)-5-美氧基-2-甲基-3-吲哚乙酸二马来酸盐（II-8）被发现是最活跃的5-LO和CO的双重抑制剂，其抑制效力高于领先化合物2-[4-(3-羟丙基)-1-哌嗪基]-乙基[1-(4-氯苯甲酰)-5-美氧基-2-甲基]-3-吲哚乙酸（CR-1015）（I）。

  DOI：

  10.1248/cpb.42.963
• 作为产物：
  描述：

  1-(2-羟基-1-氧代丙基)哌嗪 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 反应 3.0h， 以34%的产率得到1-哌嗪-1-基丙-2-醇
  参考文献：
  名称：

  Kafka, Stanislav; Cermak, Jan; Novak, Tomas, Collection of Czechoslovak Chemical Communications, 1985, vol. 50, # 5, p. 1201 - 1211

  摘要：

  DOI：

文献信息

• [EN] ROR NUCLEAR RECEPTOR MODULATORS<br/>[FR] MODULATEURS DES RÉCEPTEURS NUCLÉAIRES ROR
  申请人：ABBVIE INC

  公开号：WO2016198908A1

  公开（公告）日：2016-12-15

  The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.

  本发明提供了式(I)化合物的药物可接受的盐、前药、生物活性代谢物、立体异构体和它们的同分异构体，其中变量如本文所述定义。本发明的化合物用于治疗免疫性疾病。
• Synthesis and antileishmanial activity of 6-methoxy-4-methyl-N-[6-(substituted-1-piperazinyl)hexyl]-8-quinolinamines and related compounds
  作者：Judith L. Johnson、Leslie M. Werbel

  DOI：10.1021/jm00356a013

  日期：1983.2

  The 8-quinolinamine, 4-[6-[6-methoxy-4-methyl-8-quinolinyl)amino]hexyl]-1-piperazineethanol (1b), has been shown to be highly effective against Leishmania donovani infections in hamsters. In an effort to obtain a more potent, less toxic 8-quinolinamine, a series of analogues (2) was prepared that examined particularly the structural requirements of the terminal piperazine moiety. Of the substituted

  8-喹啉胺，4- [6- [6- [6-甲氧基-4-甲基-8-喹啉基）氨基]己基] -1-哌嗪乙醇（1b）已显示出对仓鼠利什曼原虫多诺万尼感染的高度有效。为了获得更有效，毒性较小的8-喹啉胺，制备了一系列类似物（2），它们特别检查了末端哌嗪部分的结构要求。在制备的取代的哌嗪和替代的杂环以及在2-位上甲基插入环或在5-位上芳氧基取代基的那些喹啉类似物中，仅使用2-羟丙基类似物实现了效力的增加。 （2f）。
• 二環式アミン化合物の製造方法
  申请人：東ソー株式会社

  公开号：JP2017160157A

  公开（公告）日：2017-09-14

  【課題】 二環式アミンの製造時に、副生物の生成を抑制し、二環式アミン化合物の安定的な製造方法を提供する。【解決手段】 二環式アミン化合物を製造する方法において、無機担体とアルカリ金属リン酸塩、さらにアルカリ土類金属水酸化物及び／又はヒドロキシアパタイトを無機担体に対し１．５重量％以上１５重量％未満含む触媒を用いる。【選択図】 なし

  在制造二环胺时，抑制副生成物的生成，提供二环胺化合物稳定的制造方法。在制造二环胺化合物的方法中，使用无机载体和碱金属磷酸盐，以及碱土金属氢氧化物和/或羟基磷灰石作为无机载体的催化剂，含量为1.5重量％以上但不超过15重量％。【选择图】 无
• IONIZABLE COMPOUNDS AND COMPOSITIONS AND USES THEREOF
  申请人：Nitto Denko Corporation

  公开号：US20160376229A1

  公开（公告）日：2016-12-29

  This invention includes ionizable compounds, and compositions and methods of use thereof. The ionizable compounds can be used for making nanoparticle compositions for use in biopharmaceuticals and therapeutics. More particularly, this invention relates to compounds, compositions and methods for providing nanoparticles to encapsulate active agents, such as nucleic acid agents, and to deliver and distribute the active agents to cells, tissues, organs, and subjects.

  这项发明涉及可离子化的化合物，以及其组合物和使用方法。这些可离子化的化合物可用于制备纳米粒子组合物，用于生物制药和治疗。更具体地说，这项发明涉及提供纳米粒子以包裹活性剂，如核酸剂，并将活性剂传递和分发到细胞、组织、器官和受试者的化合物、组合物和方法。
• 6-CYCLOAMINO-3-(1H-PYRROLO[2,3-b]PYRIDIN-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
  申请人：Pacaud Christophe

  公开号：US20120010208A1

  公开（公告）日：2012-01-12

  The invention relates to 6-cycloamino-3-(1H-pyrrolo[2,3-b]pyridin-4-yl)imidazo[1,2-b]pyridazine derivatives corresponding to the general formula (I) in which R 2 represents an aryl group optionally substituted with one or more halogen atoms or C 1-6 -alkyl, C 1-6 -alkyloxy, C 1-6 -alkylthio, C 1-6 -fluoroalkyl, C 1-6 -fluoroalkyloxy and —CN groups or R 2 represents a group chosen from C 1-6 -alkyl, C 1-6 -fluoroalkyl, C 3-7 -cycloalkyl or C 3-7 -cycloalkyl-C 1-6 -alkyl groups; A represents a C 1-7 -alkylene group; B represents a C 1-7 -alkylene group; L represents either a nitrogen atom optionally substituted with an R c or R d group, or a carbon atom substituted with an R e1 group and an R d group or two R e2 groups; the carbon atoms of A and of B being optionally substituted with one or more R f groups, which may be identical to or different from one another. Preparation process and therapeutic use.

  该发明涉及与一般式（I）相对应的6-环氨基-3-(1H-吡咯并[2,3-b]吡啶-4-基)咪唑并[1,2-b]吡啶衍生物，其中R2代表一个芳基，该芳基可选择性地取代一个或多个卤原子或C1-6-烷基、C1-6-烷氧基、C1-6-烷硫基、C1-6-氟烷基、C1-6-氟烷氧基和—CN基，或者R2代表从C1-6-烷基、C1-6-氟烷基、C3-7-环烷基或C3-7-环烷基-C1-6-烷基基团中选择的一种基团；A代表一个C1-7-烷基烯基；B代表一个C1-7-烷基烯基；L代表一个氮原子，该氮原子可选择性地取代为Rc或Rd基团，或者是一个碳原子，该碳原子取代为Re1基团和Rd基团或两个Re2基团；A和B的碳原子可选择性地取代为一个或多个Rf基团，这些基团可以相同也可以不同。制备方法和治疗用途。